Home Health & Medical Medical Devices

FREND COVID-19 Ag+FLU A&B

Qualitative test for COVID-19 Ag + FLU A&B

faceboox pinterest twitter share

Negotiable Min Order Quantity Unit

Required Quantity

Place of Origin: South Korea

Payment Terms: Others

Production method: OBM

Shipping / Lead Time: Negotiable / Negotiable

Keyword: port

Category: Medical Devices

SEND TO SUPPLIER INQUIRY

NanoEnTek Inc.

Recent Visit: Nov 25, 2024

Country / Year Established: South Korea / 2000

Business type: Manufacturer

Verified Certificate

TRADE TOWER

DUNS

Minisite Follow Company

PRODUCT DESCRIPTION COMPANY INFORMATION Related Products

Product name	FREND COVID-19 Ag+FLU A&B	Certification	-
Category	Medical Devices	Material	-
Keyword	port	Unit Size	-
Brand name	-	Unit Weigh	-
origin	South Korea	Stock	0
Supply type	OBM	HS code	-

Product Information

The FREND™ COVID-19 Ag + Flu A&B is a fluorescence immunoassay (FIA) for use with the FREND™ System. It is designed for the qualitative and simultaneous detection of the nucleocapsid protein of SARS-CoV-2 and Influenza A&B virus. It measures directly from nasopharyngeal swab specimens.

KEY FEATURES & BENEFITS

- 3 minutes | Fast result

- 2 steps | Easy to use

- Microfluidic Qualitative Immunoassay

- LIS connectivity (data management)

- COVID-19 Ag | 95.56 % & 99.66% Percent Agreement

- Influenza A | 100.00 % & 99.67 % Percent Agreement

- Influenza B | 97.50 % & 98.66 % Percent Agreement

Microfluidic Qualitative Immunoassay

FREND™ COVID-19 Ag + Flu A&B

The FREND™ COVID-19 Ag + Flu A&B is a fluorescence immunoassay (FIA) for use with the FREND™ System. It is designed for the qualitative and simultaneous detection of the nucleocapsid protein of SARS-CoV-2 and Influenza A&B virus. It measures directly from nasopharyngeal swab specimens.

Instructions for use

Accurate result in 3 minutes!

With just simple steps of operation, the FREND™ system supports quick decision-making.

Performance evaluation

Clinical agreement study

[COVID-19 Ag]

The total of 338 clinical samples (45 positive and 293 negative) confirmed with RT-PCR were tested.

It shows 95.56% PPA (Positive Percent Agreement) and 99.66% NPA (Negative Percent Agreement) shown as below.

[Influenza A]

The total of 338 clinical samples (38 positive and 300 negative) confirmed with RT-PCR were tested.

It shows 100% PPA (Positive Percent Agreement) and 99.67% NPA (Negative Percent Agreement) shown as below.

[Influenza B]

The total of 338 clinical samples (40 positive and 298 negative) confirmed with RT-PCR were tested.

It shows 97.50% PPA (Positive Percent Agreement) and 98.66% NPA (Negative Percent Agreement) shown as below.

Effective Data Management

Laboratory Information System Connectivity

In the event of a pandemic, the management of a vast amount of clinical result is important. However, many laboratories face the challenge in arranging the essential information effectively⁽¹⁾.

The FREND™ System which is LIS compatible provide following features: